Fig. 4. CXCL7 promotes sphere formation and gliomagenesis of glioma cells.

(A), Sphere formation capacity of GL261-FGL2^KO, DBT-FGL2^KO, and LLC-FGL2^KO tumor cells in cancer stem cell culture media when cocultured with mFGL2^hi conditioned media (CM)-wired BMDMs pretreated with/without IgGoranti-CXCL7. Left: representative photos of sphere formation in the indicated system. Right: quantification of relative sphere formation. Scale bar, 400 μm. Data are presented as the mean ± SD and were analyzed by 1-way ANOVA (n = 6 per group). Representative data from 2–3 independent experiments are shown. **P < 0.01, ***P < 0.001. (B), Survival curves of C57BL/6 mice (N = 7) implanted with FGL2^hi tumor cells treated with anti-CXCL7 or IgG antibody. Mice were implanted with GL261-FGL2^hi tumor cells (2000 cells). At day 7 post implantation, 50 μg anti-CXCL7 or 50 μg IgG antibody were injected into the brain and survival time of mice was monitored. The survival curves were generated by Kaplan-Meier analysis, and the log-rank test was used to compare overall survival between groups. (C), Survival curves of C57BL/6 mice (N = 4) implanted with 5 × 10⁴ GL261-FGL2^low-RFP or GL261-FGL2^low-CXCL7OE cells. The survival curves were generated by Kaplan–Meier analysis, and the log-rank test was used to compare overall survival between groups.